MX359403B - Combinaciones farmacéuticas que comprenden un inhibidor de b-raf, un inhibidor de egfr, y opcionalmente un inhibidor de pi3k-alfa. - Google Patents

Combinaciones farmacéuticas que comprenden un inhibidor de b-raf, un inhibidor de egfr, y opcionalmente un inhibidor de pi3k-alfa.

Info

Publication number
MX359403B
MX359403B MX2015001732A MX2015001732A MX359403B MX 359403 B MX359403 B MX 359403B MX 2015001732 A MX2015001732 A MX 2015001732A MX 2015001732 A MX2015001732 A MX 2015001732A MX 359403 B MX359403 B MX 359403B
Authority
MX
Mexico
Prior art keywords
inhibitor
optionally
pi3k
egfr
raf
Prior art date
Application number
MX2015001732A
Other languages
English (en)
Other versions
MX2015001732A (es
Inventor
Stuart Darrin
Caponigro Giordano
Moutouh-Deparseval Laure
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48980368&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX359403(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2015001732A publication Critical patent/MX2015001732A/es
Publication of MX359403B publication Critical patent/MX359403B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Una combinación farmacéutica, la cual comprende: (a) un inhibidor de B-Raf, (b) un inhibidor del receptor del factor de crecimiento epidérmico (EGFR) y, opcionalmente, (c) un inhibidor de PI3K; los usos de esta combinación en el tratamiento de enfermedades proliferativas; y los métodos para el tratamiento de un sujeto que padezca de una enfermedad proliferativa, los cuales comprenden administrar una cantidad terapéuticamente efectiva de esta combinación.
MX2015001732A 2012-08-07 2013-08-05 Combinaciones farmacéuticas que comprenden un inhibidor de b-raf, un inhibidor de egfr, y opcionalmente un inhibidor de pi3k-alfa. MX359403B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261680473P 2012-08-07 2012-08-07
PCT/US2013/053619 WO2014025688A1 (en) 2012-08-07 2013-08-05 Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor

Publications (2)

Publication Number Publication Date
MX2015001732A MX2015001732A (es) 2015-06-03
MX359403B true MX359403B (es) 2018-09-26

Family

ID=48980368

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015001732A MX359403B (es) 2012-08-07 2013-08-05 Combinaciones farmacéuticas que comprenden un inhibidor de b-raf, un inhibidor de egfr, y opcionalmente un inhibidor de pi3k-alfa.

Country Status (39)

Country Link
US (1) US9474754B2 (es)
EP (2) EP3574904A1 (es)
JP (3) JP6342396B2 (es)
KR (1) KR102112885B1 (es)
CN (1) CN104519887B (es)
AR (1) AR092045A1 (es)
AU (1) AU2013299841B8 (es)
CA (1) CA2879548C (es)
CL (1) CL2015000294A1 (es)
CO (1) CO7200273A2 (es)
CY (1) CY1122143T1 (es)
DK (1) DK2882440T3 (es)
EA (1) EA028420B1 (es)
EC (1) ECSP15008695A (es)
ES (1) ES2717911T3 (es)
GT (1) GT201500025A (es)
HK (1) HK1211831A1 (es)
HR (1) HRP20190537T1 (es)
HU (1) HUE042877T2 (es)
IL (1) IL236934B (es)
IN (1) IN2015DN00450A (es)
JO (1) JOP20130236B1 (es)
LT (1) LT2882440T (es)
MA (1) MA37829A1 (es)
MX (1) MX359403B (es)
MY (1) MY176031A (es)
NZ (1) NZ703940A (es)
PE (2) PE20150673A1 (es)
PH (1) PH12015500246B1 (es)
PL (1) PL2882440T3 (es)
PT (1) PT2882440T (es)
RS (1) RS58734B1 (es)
SG (1) SG11201500321YA (es)
SI (1) SI2882440T1 (es)
TN (1) TN2015000027A1 (es)
TR (1) TR201904980T4 (es)
TW (1) TWI607754B (es)
UA (1) UA115786C2 (es)
WO (1) WO2014025688A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3574904A1 (en) * 2012-08-07 2019-12-04 Array Biopharma, Inc. Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
SG11201507730UA (en) 2013-03-21 2015-10-29 Novartis Ag Combination therapy comprising a b-raf inhibitor and a second inhibitor
WO2015145388A2 (en) * 2014-03-27 2015-10-01 Novartis Ag Methods of treating colorectal cancers harboring upstream wnt pathway mutations
ES2686549T3 (es) * 2014-06-16 2018-10-18 Worldwide Innovative Network Método para seleccionar una triterapia personalizada para el tratamiento del cáncer
WO2016193955A1 (en) * 2015-06-04 2016-12-08 Giorgio Stassi Combinations of kinase inhibitors for treating colorectal cancer
US20180256557A1 (en) * 2015-08-28 2018-09-13 Giordano Caponigro Pharmaceutical combination comprising (a) the alpha-isoform specific pi3k inhibitor alpelisib (byl719) and (b) an akt inhibitor, preferably mk-2206, afuresertib or uprosertib, and the use thereof in the treatment/prevention of cancer
JP2018525402A (ja) * 2015-08-28 2018-09-06 ノバルティス アーゲー Ｐｉ３ｋ阻害剤のアルペリシブおよびｂ−ｒａｆ阻害剤のダブラフェニブを含む組合せ医薬、がんの治療または予防におけるそのような組合せの使用
WO2017066664A1 (en) * 2015-10-16 2017-04-20 Millennium Pharmaceuticals, Inc. Combination therapy including a raf inhibitor for the treatment of colorectal cancer
CN109890386B (zh) 2016-06-03 2022-05-24 阵列生物制药公司 药物组合
EP3515446B1 (en) 2016-09-19 2023-12-20 Novartis AG Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
CN110494166B (zh) 2017-05-02 2022-11-08 诺华股份有限公司 组合疗法
RU2020108192A (ru) * 2017-08-03 2021-09-03 Новартис Аг Терапевтическая комбинация ингибитора тирозинкиназы egfr третьего поколения и ингибитора raf
LT3860998T (lt) 2018-10-05 2024-06-25 Annapurna Bio Inc. Junginiai ir kompozicijos, skirti gydyti būkles, susijusias su apj receptoriaus aktyvumu
TWI849043B (zh) * 2019-01-25 2024-07-21 英屬開曼群島商百濟神州有限公司 B-raf激酶二聚體抑制劑之穩定固體分散體、製備方法及其用途
WO2020164997A1 (en) * 2019-02-12 2020-08-20 Bayer Aktiengesellschaft Combination of pi3k-inhibitors
KR102881316B1 (ko) 2019-05-13 2025-11-05 노파르티스 아게 암 치료를 위한 raf 억제제로서의 n-(3-(2-(2-하이드록시에톡시)-6-모르폴리노피리딘-4-일)-4-메틸페닐)-2 (트리플루오로메틸)이소니코틴아미드의 새로운 결정질 형태
WO2023145530A1 (ja) * 2022-01-27 2023-08-03 国立大学法人東北大学 癌治療剤
CA3257280A1 (en) 2022-05-25 2023-11-30 Msd International Gmbh COMBINATION OF A BRAF INHIBITOR, AN EGFR INHIBITOR AND A PD-1 ANTAGONIST FOR THE TREATMENT OF COLORECTAL CANCER MSI-H/DMMR, WITH BRAF V600E MUTATION
AU2023351185A1 (en) * 2022-09-26 2025-04-24 Amgen Inc. Combinations of a b-raf inhibitor, and an anti-egfr antibody for the treatment of cancer
WO2025003956A1 (en) 2023-06-30 2025-01-02 Pfizer Inc. High drug loading formulations of encorafenib

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
ES2430614T3 (es) 2007-04-10 2013-11-21 Exelixis, Inc. Métodos de tratamiento del cáncer usando inhibidores de piridopirimidinona de PI3K alfa
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
EP2470898A4 (en) * 2009-08-24 2013-03-13 Genentech Inc DETERMINING SENSITIVITY OF CELLS TO B-RAF INHIBITOR TREATMENT IN DETECTION OF K-RAS MUTATIONS AND MEASURING RTK EXPRESSION LEVELS
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
EP2488184A4 (en) * 2009-10-12 2013-04-24 Glaxosmithkline Llc COMBINATION
US20120045433A1 (en) 2010-08-17 2012-02-23 Kapil Dhingra Combination therapy
TR201802943T4 (tr) * 2010-11-08 2018-03-21 Novartis Ag (S)-pirolidin-1,2-dikarboksilik asit 2-amid 1-({4-metil-5-[2-(2,2,2-trifloro-1,1-dimetil-etil)-piridin-4-il]-tiyazol-2-il}amid)'in egfr'ye bağlı hastalıkların veya egfr familya üyelerini hedefleyen ajanlara karşı direnç edinmiş hastalıkların tedavisinde kullanımı.
EP2776413A1 (en) 2011-11-10 2014-09-17 Memorial Sloan-Kettering Cancer Center TREATMENT OF OVARIAN CANCER WITH 2-AMINO-4H-NAPHTHO[1,2-b]PYRAN-3-CARBONITRILES
BR112014011223A8 (pt) * 2011-11-11 2023-01-31 Novartis Ag Método de tratar uma doença proliferativa
EP3574904A1 (en) * 2012-08-07 2019-12-04 Array Biopharma, Inc. Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor

Also Published As

Publication number Publication date
CY1122143T1 (el) 2020-11-25
NZ703940A (en) 2018-04-27
RS58734B1 (sr) 2019-06-28
HK1211831A1 (zh) 2016-06-03
EA028420B1 (ru) 2017-11-30
PH12015500246A1 (en) 2015-03-30
AR092045A1 (es) 2015-03-18
PL2882440T3 (pl) 2019-07-31
JP6342396B2 (ja) 2018-06-13
PT2882440T (pt) 2019-04-23
IN2015DN00450A (es) 2015-06-26
SG11201500321YA (en) 2015-04-29
ES2717911T3 (es) 2019-06-26
HRP20190537T1 (hr) 2019-06-28
AU2013299841A1 (en) 2015-02-12
KR102112885B1 (ko) 2020-05-19
EP2882440A1 (en) 2015-06-17
IL236934B (en) 2018-11-29
JP2018109022A (ja) 2018-07-12
CA2879548C (en) 2020-07-21
DK2882440T3 (da) 2019-05-06
BR112015002384A8 (pt) 2023-01-31
SI2882440T1 (sl) 2019-05-31
MY176031A (en) 2020-07-22
WO2014025688A1 (en) 2014-02-13
TR201904980T4 (tr) 2019-05-21
AU2013299841B8 (en) 2017-01-05
JOP20130236B1 (ar) 2021-08-17
TW201410247A (zh) 2014-03-16
HUE042877T2 (hu) 2019-07-29
PH12015500246B1 (en) 2015-03-30
JP6974669B2 (ja) 2021-12-01
KR20150040905A (ko) 2015-04-15
US9474754B2 (en) 2016-10-25
EA201590332A1 (ru) 2015-06-30
CN104519887B (zh) 2017-06-27
EP2882440B1 (en) 2019-02-27
GT201500025A (es) 2017-09-28
LT2882440T (lt) 2019-04-25
TN2015000027A1 (en) 2016-06-29
CO7200273A2 (es) 2015-02-27
AU2013299841A8 (en) 2017-01-05
PE20191655A1 (es) 2019-11-07
ECSP15008695A (es) 2019-03-29
JP2020019780A (ja) 2020-02-06
CL2015000294A1 (es) 2015-05-08
CA2879548A1 (en) 2014-02-13
EP3574904A1 (en) 2019-12-04
BR112015002384A2 (pt) 2017-07-04
US20150265616A1 (en) 2015-09-24
UA115786C2 (uk) 2017-12-26
MX2015001732A (es) 2015-06-03
PE20150673A1 (es) 2015-05-20
AU2013299841B2 (en) 2016-11-24
MA37829A1 (fr) 2017-01-31
HK1204976A1 (en) 2015-12-11
CN104519887A (zh) 2015-04-15
JP6595024B2 (ja) 2019-10-23
TWI607754B (zh) 2017-12-11
JP2015524472A (ja) 2015-08-24

Similar Documents

Publication Publication Date Title
MX359403B (es) Combinaciones farmacéuticas que comprenden un inhibidor de b-raf, un inhibidor de egfr, y opcionalmente un inhibidor de pi3k-alfa.
AR091876A1 (es) Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
CY1124311T1 (el) Παρεμποδιστες dna-pk
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
CO7350624A2 (es) Inhibidores de la tirosina-quinasa de bruton
NI201000105A (es) Régimen de dosificación asociado con ésteres de paliperidona inyectables de acción prolongada.
MX2016004580A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
MX2013006591A (es) Formas farmaceuticas orales de liberacion controlada de farmacos escasamente solubles y los usos de estas.
AR092177A1 (es) Metodos para tratar o prevenir asma administrando un antagonista de il-4r
DOP2015000108A (es) Compuestos de pirrolopirimidina como inhibidores de quinasas
CL2015002807A1 (es) Terapia de combinación
EA201490194A1 (ru) Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака
CL2015000744A1 (es) Combinación de regorafenib y ácido acetilsalicílico para el tratamiento del cáncer.
MX366317B (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
MX2015009045A (es) Composiciones y metodos para tratar el dolor severo.
NI201400112A (es) Tratamiento del cáncer con inhibidores tor cinasa
CL2018003421A1 (es) Combinaciones farmacéuticas.
CO7151543A2 (es) Combinaciones terapéuticas y métodos para tratar el melanoma
CL2012002858A1 (es) Combinación farmacéutica que comprende 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencilamidazol-2-il-quinolin-2-ona y al menos un inhibidor de mtor; método de tratamiento; y uso para el tratamiento y la prevención de una enfermedad proliferativa tal como cáncer de mama, tumores neuroendocrinos y linfonas, entre otras.
CO7111317A2 (es) Método para el tratamiento de enfermedades ginecológicas
EA201500232A1 (ru) Три(гетеро)арилпиразолы и их применение
CR20110687A (es) Procedimientos de uso del factor liberador de corticotropina para el tratamiento de cancer
AR076479A1 (es) Composiciones farmaceuticas para terapias de mantenimiento que contienen como ingrediente activo un anticuerpo que reconoce el antigeno leucocitario humano (hla) de clase i
UY35033A (es) Formulación en comprimidos de un inhibidor de la fosfatidilinositol 3-cinasa
AR105142A1 (es) Métodos de tratamiento del glioblastoma multiforme con terapia de células t

Legal Events

Date Code Title Description
FG Grant or registration